Publications by authors named "K N Mmasa"
Article Synopsis
- The study examined postpartum depression (PPD) prevalence among women living with HIV (WLHIV) in Botswana using the Edinburgh Postnatal Depression Scale (EPDS), involving 300 WLHIV and 131 HIV-uninfected women.
- It found that 8% of WLHIV experienced PPD symptoms at various postpartum follow-ups, which was slightly higher than the 6.9% in HIV-uninfected women, but no significant link was found between HIV status and PPD.
- However, WLHIV on efavirenz-based antiretroviral therapy (ART) had higher odds of PPD compared to those on dolutegravir-based ART, indicating a possible connection between type of ART and PPD symptoms
Background: There are little data on changes in insulin sensitivity during the first few years of life following in utero human immunodeficiency virus (HIV) and antiretroviral (ARV) exposure.
Methods: The Tshilo Dikotla study enrolled pregnant persons with HIV (PWH) (receiving tenofovir/emtricitabine or lamivudine plus dolutegravir or efavirenz) and pregnant individuals without HIV, as well as their liveborn children. Newborns were randomized to receive either zidovudine (AZT) or nevirapine (NVP) postnatal prophylaxis.
Background: Few data exist on early-life metabolic perturbations in newborns with perinatal HIV and antiretroviral (ARV) exposure but uninfected (HEU) compared to those perinatally HIV unexposed and uninfected (HUU).
Methods: We enrolled pregnant persons with HIV (PWH) receiving tenofovir (TDF)/emtricitabine or lamivudine (XTC) plus dolutegravir (DTG) or efavirenz (EFV), and pregnant individuals without HIV, as well as their liveborn infants. Newborns were randomized to receive either zidovudine (AZT) or nevirapine (NVP) postnatal prophylaxis.
Background: There are few data on the prevalence of gestational diabetes (GDM) in pregnant women living with HIV (WLHIV) in sub-Saharan Africa, particularly those using integrase strand transfer inhibitors such as dolutegravir (DTG).
Methods: We prospectively enrolled pregnant WLHIV and pregnant women without HIV ≥18 years old in Gaborone, Botswana, excluding those with pre-existing diabetes. We screened for GDM using a 75 g oral glucose tolerance test (OGTT) performed at 24-28 weeks' gestation or at the earliest prenatal visit for those presenting after 28 weeks.